RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-18.32%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$875M
AUM Growth
+$875M
(-12%)
Cap. Flow
+$65.9M
Cap. Flow
% of AUM
7.53%
Top 10 Holdings %
Top 10 Hldgs %
28.77%
Holding
95
New
7
Increased
32
Reduced
30
Closed
6
Top Buys
| 1 |
BLUE
bluebird bio
BLUE
|
$11.7M |
| 2 |
Centene
CNC
|
$9.22M |
| 3 |
Biogen
BIIB
|
$9.03M |
| 4 |
UnitedHealth
UNH
|
$8.82M |
| 5 |
Neurocrine Biosciences
NBIX
|
$8.53M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
$10.1M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$7.52M |
| 3 |
Incyte
INCY
|
$7.03M |
| 4 |
Exelixis
EXEL
|
$5.95M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
$5.6M |
Sector Composition
| 1 | Healthcare | 93.94% |
| 2 | Energy | 0.12% |
| 3 | Technology | 0.11% |
| 4 | Financials | 0.09% |
| 5 | Communication Services | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$281B
| $31.5M | 3.6% | 126,396 +35,396 | +39% | +$8.82M |
|
2
Cigna
CI
$80.3B
| $30.3M | 3.47% | 159,691 -15,000 | -9% | -$2.85M |
|
3
Medtronic
MDT
$119B
| $27.3M | 3.12% | 300,403 +50,529 | +20% | +$4.6M |
|
4
CVS Health
CVS
$92.8B
| $26.8M | 3.06% | 408,868 -30,000 | -7% | -$1.97M |
|
5
Becton Dickinson
BDX
$55.3B
| $25.9M | 2.96% | 115,000 +35,000 | +44% | +$7.89M |
|
6
Humana
HUM
$36.5B
| $23.6M | 2.7% | 82,400 +29,400 | +55% | +$8.42M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $22.4M | 2.56% | 230,429 -12,900 | -5% | -$1.26M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $21.9M | 2.51% | 132,425 -10,040 | -7% | -$1.66M |
|
|
ABMD
9
DELISTED
Abiomed Inc
ABMD
| $21.2M | 2.43% | 65,310 +9,609 | +17% | +$3.12M |
|
10
Elevance Health
ELV
$71.8B
| $20.7M | 2.36% | 78,645 +8,645 | +12% | +$2.27M |
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $20.6M | 2.35% | 165,818 +39,496 | +31% | +$4.9M |
|
12
Bristol-Myers Squibb
BMY
$96B
| $19.2M | 2.2% | 370,000 +40,000 | +12% | +$2.08M |
|
13
Abbott
ABT
$231B
| $19.1M | 2.19% | 264,552 | – | – |
|
|
14
Exelixis
EXEL
$10.1B
| $18.9M | 2.16% | 958,994 -302,420 | -24% | -$5.95M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $18.5M | 2.11% | 946,060 +29,009 | +3% | +$567K |
|
16
NovoCure
NVCR
$1.38B
| $18.2M | 2.09% | 545,000 +145,000 | +36% | +$4.85M |
|
|
17
Biogen
BIIB
$19.4B
| $18.1M | 2.06% | 60,000 +30,000 | +100% | +$9.03M |
|
|
18
Incyte
INCY
$16.5B
| $16.9M | 1.94% | 266,416 -110,500 | -29% | -$7.03M |
|
19
Nektar Therapeutics
NKTR
$568M
| $16.9M | 1.94% | 515,000 +209,607 | +69% | +$6.89M |
|
20
Esperion Therapeutics
ESPR
$448M
| $16.3M | 1.86% | 353,961 | – | – |
|
|
DPLO
21
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $16.2M | 1.85% | 1,203,405 +28,994 | +2% | +$390K |
|
|
22
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15M | 1.72% | 176,549 -88,300 | -33% | -$7.52M |
|
23
AbbVie
ABBV
$372B
| $15M | 1.71% | 162,415 +32,415 | +25% | +$2.99M |
|
|
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.5M | 1.66% | 371,858 +5,471 | +1% | +$213K |
|
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $14.4M | 1.64% | 201,091 +119,414 | +146% | +$8.53M |
|